Anatara Lifesciences Ltd (AU:ANR) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Anatara Lifesciences is advancing its GaRP-IBS clinical trial, having reached the minimum participant requirement for Stage 2 and pausing recruitment from December 13, 2024. The trial aims to explore new treatments for Irritable Bowel Syndrome, with headline results expected in the first quarter of 2025. The company’s proactive recruitment strategy has successfully engaged participants across key sites.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Serious Drop Is in the Cards,’ Says Analyst About Palantir Stock
- Walmart’s (NYSE:WMT) $2.3 Billion Deal with Vizio Closes
- Ford (NYSE:F) Electric Vehicle Sales Hit New Record
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
